2023 World Conference on Lung Cancer (Posters)-P1.25. Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study

P1.25. Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study - PDF(Slides)

Back to course

Pdf Summary

The Phase 2 LCMC3 study evaluated the use of neoadjuvant atezolizumab (anti-PD-L1) in patients with resectable non-small cell lung cancer (NSCLC). This subgroup analysis focused on the outcomes by age, specifically comparing patients aged 65 years and older with those younger than 65 years. The study found that there was no significant difference in the major pathologic response (MPR) rate, 3-year disease-free survival (DFS) rate, or 3-year overall survival (OS) rate between the age groups. The MPR rate was 20% in both groups. The 3-year DFS rate was 78% for the older group and 67% for the younger group, and the 3-year OS rate was 88% for the older group and 77% for the younger group. <br /><br />Safety was also examined, and it was found that treatment-related adverse events (AEs) occurred in 65% of the older group and 68% of the younger group. Grade 3/4 treatment-related AEs occurred in 12% of the older group and 20% of the younger group. The most common treatment-related AEs were fatigue, diarrhea, and nausea in both age groups.<br /><br />The analysis also looked at T-cell dynamics in tumor tissue. It was found that there were significant differences in T-cell clonality between the age groups before and after neoadjuvant atezolizumab treatment for certain histological subtypes. However, there were no differences in T-cell richness between the age groups.<br /><br />Overall, neoadjuvant atezolizumab was found to be well tolerated by both age groups, and no new safety concerns were identified. The differences in T-cell clonality observed between the age groups warrant further investigation. The study was sponsored by Genentech, Inc.

Asset Subtitle

Carolyn Presley

Meta Tag

Speaker Carolyn Presley

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

Phase 2 LCMC3 study

neoadjuvant atezolizumab

anti-PD-L1

resectable non-small cell lung cancer

age groups

major pathologic response rate

3-year disease-free survival rate

3-year overall survival rate

treatment-related adverse events

T-cell dynamics